Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation

BACKGROUND: Overexpression of AXL receptor tyrosine kinase (AXL) in various human cancers correlates with reduced patients overall survival and resistance to first line therapies. Therefore, several AXL tyrosine kinase inhibitors (TKIs) are currently under clinical evaluation. RESULTS: AXL TKI BMS77...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauter, Markus, Weber, Anja, Torka, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555758/
https://www.ncbi.nlm.nih.gov/pubmed/31171001
http://dx.doi.org/10.1186/s12964-019-0377-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555758/
https://www.ncbi.nlm.nih.gov/pubmed/31171001
http://dx.doi.org/10.1186/s12964-019-0377-8

Ejemplares similares